UTHR:NGS-United Therapeutics Corporation (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 275.19

Change

+0.52 (+0.19)%

Market Cap

USD 5.48B

Volume

0.38M

Analyst Target

USD 144.78
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

United Therapeutics Corp is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.70 (+0.35%)

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

+9.97 (+0.97%)

USD 110.51B
MRNA Moderna Inc

-5.20 (-3.58%)

USD 57.87B
BNTX BioNTech SE

-3.92 (-4.08%)

USD 24.18B
ARGX argenx NV ADR

-1.34 (-0.35%)

USD 23.09B
ALNY Alnylam Pharmaceuticals Inc

+0.34 (+0.21%)

USD 20.25B
GMAB Genmab AS

-0.22 (-0.83%)

USD 18.17B
BGNE BeiGene Ltd

-3.80 (-2.28%)

USD 17.74B
RPRX Royalty Pharma Plc

-0.28 (-1.03%)

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

-0.73 (-0.87%)

USD 15.32B

ETFs Containing UTHR

MUUSAS:SW UBS (Irl) Fund Solutions .. 195.50 % 0.00 %

-0.28 (0%)

USD 0.44B
SANE 4.17 % 0.00 %

N/A

N/A
FTXH First Trust Nasdaq Pharma.. 4.07 % 0.60 %

-0.06 (0%)

USD 0.02B
BIOT:SW L&G Pharma Breakthrough U.. 2.86 % 0.00 %

-0.11 (0%)

N/A
FXH First Trust Health Care A.. 2.72 % 0.63 %

-0.58 (0%)

USD 1.25B
SRHQ Elevation Series Trust - .. 2.04 % 0.00 %

-0.32 (0%)

USD 0.14B
DSMC ETF Series Solutions 1.61 % 0.00 %

-0.53 (0%)

USD 0.06B
KRUZ 1.45 % 0.00 %

N/A

N/A
JMEE JPMorgan Market Expansion.. 0.78 % 0.00 %

-0.81 (0%)

USD 1.08B
THNZ:XETRA L&G Global Thematic ESG E.. 0.73 % 0.00 %

-0.06 (0%)

USD 4.34M
ETHO Etho Climate Leadership U.. 0.00 % 0.45 %

-0.60 (0%)

USD 0.18B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

-1.52 (0%)

USD 1.15B
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

-0.39 (0%)

CAD 9.66M
FNX First Trust Mid Cap Core .. 0.00 % 0.62 %

-1.85 (0%)

USD 1.15B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

+0.49 (+0%)

USD 0.11B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-0.54 (0%)

USD 0.26B
FSMD Fidelity Small-Mid Factor 0.00 % 0.00 %

-0.42 (0%)

USD 0.33B
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-1.20 (0%)

USD 0.02B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

-0.09 (0%)

USD 8.18M
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.05 (+0%)

USD 0.02B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-0.01 (0%)

USD 0.02B
BIOT 0.00 % 0.00 %

N/A

N/A
GLRY Inspire Faithward Mid Cap.. 0.00 % 0.00 %

-0.30 (0%)

USD 0.06B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

-9.70 (0%)

USD 5.63M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

-0.19 (0%)

USD 5.63M
KONG Formidable Fortress ETF 0.00 % 0.00 %

-0.12 (0%)

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.15% 73% C 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.15% 73% C 84% B
Trailing 12 Months  
Capital Gain 27.29% 78% C+ 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.29% 78% C+ 77% C+
Trailing 5 Years  
Capital Gain 220.03% 92% A 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 220.03% 92% A 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 29.89% 79% B- 85% B
Dividend Return 29.89% 79% B- 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.15% 81% B- 59% D-
Risk Adjusted Return 95.97% 100% F 96% N/A
Market Capitalization 5.48B 98% N/A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.80 39% 62%
Price/Book Ratio 1.83 65% 50%
Price / Cash Flow Ratio 12.24 5% 21%
Price/Free Cash Flow Ratio 6.24 4% 33%
Management Effectiveness  
Return on Equity 20.08% 98% 90%
Return on Invested Capital 14.58% 89% 84%
Return on Assets 12.25% 99% 97%
Debt to Equity Ratio 5.01% 63% 77%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector